News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
243 Results
Type
Article (33)
Press Release (210)
Section
Business (119)
Deals (15)
Drug Development (52)
FDA (3)
Job Trends (2)
News (164)
Policy (9)
Tag
Academia (1)
Alliances (9)
Approvals (3)
Best Places to Work (2)
Clinical research (47)
COVID-19 (4)
Data (5)
Diagnostics (1)
Earnings (66)
Events (38)
FDA (3)
Government (2)
Healthcare (7)
Infectious disease (4)
IPO (8)
Layoffs (1)
Legal (3)
Medical device (1)
Medtech (1)
Mergers & acquisitions (7)
NextGen Class of 2024 (1)
Northern California (1)
People (38)
Phase I (17)
Phase II (30)
Phase III (17)
Pipeline (2)
Preclinical (2)
Real estate (2)
Regulatory (5)
Research institute (1)
Startups (8)
United States (13)
Date
Last 365 days (27)
2024 (25)
2023 (33)
2022 (35)
2021 (30)
2020 (31)
2019 (27)
2018 (17)
2016 (2)
2015 (1)
2014 (1)
2013 (14)
2012 (27)
Location
Asia (27)
California (1)
Europe (48)
Maryland (2)
Massachusetts (1)
Minnesota (1)
New York (8)
Northern California (1)
243 Results for "immunovant".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
November 8, 2024
·
15 min read
Press Releases
Immunovant Provides Update on Graves’ Disease Development Program
September 9, 2024
·
6 min read
Press Releases
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
September 5, 2024
·
1 min read
Business
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024.
May 29, 2024
·
14 min read
Policy
Immunovant Awarded U.S. Patent for IMVT-1402
Immunovant, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 for IMVT-1402, the Company’s second-generation antibody targeting the neonatal fragment crystallizable receptor.
March 12, 2024
·
4 min read
Press Releases
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
October 29, 2024
·
1 min read
Pharm Country
Immunovant Announces Pricing of $450 Million Common Stock Financing
Immunovant, Inc. announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions.
September 27, 2023
·
4 min read
Business
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
August 6, 2024
·
10 min read
Business
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
February 12, 2024
·
11 min read
Pharm Country
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Immunovant, Inc. today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am ET.
January 3, 2024
·
1 min read
1 of 25
Next
